Skip to content

Yishengukang Decoction for strengthening the healthy, detoxifying and removing blood stasis in the treatment of cancerous somatic pain:A Multi-Center Randomized Controlled Trial

Yishengukang Decoction for strengthening the healthy, detoxifying and removing blood stasis in the treatment of cancerous somatic pain:A Multi-Center Randomized Controlled Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043765
Enrollment
Unknown
Registered
2021-02-28
Start date
2021-03-15
Completion date
Unknown
Last updated
2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinomatous somatic pain

Interventions

Sponsors

Qinglin Zhang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-80 years; 2) Accordance with the diagnostic criteria of Western medicine for carcinomatous somatic pain; 3) TCM syndrome differentiation belongs to kidney deficiency and (or) stagnation of blood stasis and toxin; 4) NRS > 3 for moderate to severe cancer somatic pain; 5) KPS > 30; 6) The expected survival time Will be more than 3 months; 7) Voluntarily accept the study and sign the letter of understanding.

Exclusion criteria

Exclusion criteria: 1) Radiotherapy, chemotherapy or nerve block therapy were applied to the affected or painful part of the tumor within 1 month before the beginning of the observation period; 2) Non cancerous pain, as if accompanied by tumor emergency related pain, tumor related other neuropathic pain; 3) Have a history of drug abuse or addiction; 4) Allergic to the test drug; 5) Patients with severe organ dysfunction; 6) Those who can't cooperate with the treatment plan and can't evaluate their pain and general condition.

Design outcomes

Primary

MeasureTime frame
NRS;

Secondary

MeasureTime frame
KPS score;Frequency of pain outbreaks;SRE;QLQ-C30;

Countries

China

Contacts

Public ContactLi Feng

Cancer Hospital of Chinese Academy Medical Sciences

fengli663@126.com+86 18618147576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026